. Author manuscript; available in PMC: 2020 May 1.

Published in final edited form as: Gynecol Oncol. 2019 Feb 23;153(2):217–222. doi: 10.1016/j.ygyno.2019.02.011

Table 4.

Summary of studies characterizing the tumor microenvironment in homologous recombination deficient ovarian carcinoma.

Author (year)	No. cases	No. HRD (%)	IHC markers	Associations with HRD ovarian carcinoma
Morse (current)	250	98 (39.2)	CD3, CD68	HRD ovarian carcinoma enriched for both CD3+ TILs and CD68+ TAMs, HRD and CD3+ TILs each independently prognostic for improved OS
Clarke (2009) (26)	40	18 (45.0)	CD3, CD4, CD8, CD20, CD43, CD 117, granzyme-B	CD8+ TILs correlated with BRCA1 mutation or loss of expression and with improved OS
McAlpine (2012) (24)	131	52 (39.7)	CD3, CD4, CD8, CD20, FOXP3, and TIA-1	Higher CD20+ and TIA-1 immune infiltrate in cases with BRCA1/2 mutations or BRCA1 methylation
Soslow (2012) (25)	43	31 (72.1)	TIL assessment not specified	TILs enriched in BRCA1, but not BRCA2 mutated ovarian carcinoma
Strickland (2016) (27)	53	37 (69.8)	CD3, CD4, CD8, CD20, PD-1, and PD-L1	CD3+ TILs and CD8+ TILs enriched in HRD ovarian carcinoma and CD3+ TILs associated with improved OS

HRD, homologous recombination deficient; IHC, immunohistochemistry; TIL, tumor infiltrating lymphocytes; TAM, tumor-associated macrophages; OS, overall survival.